This morning VectoIQ, which intends to combine with Nikola Motors, filed an 8-K this morning containing a new presentation slide deck. This deck is intended to accompany the analyst day scheduled for Monday, April 6. This virtual event is for sell-side analysts with interest in covering Nikola once the deal with VectoIQ closes. At first blush, the presentation is essentially the same as the one that was released on March 3, 2020, when the business combination was announced. I could only find some slight changes to the timeline for production rollouts, with some milestones pushed out a few months.
These changes have to be expected with everything going on right now and frankly should be understandable. They also added a fifth section to the presentation called the Business Model Walkthrough (slide 38), which is a deeper dive into the key drivers and assumptions. This effort is to guide the sell-side analysts as they build their financial models. I will dig into those over the weekend and come back to you next week.
Real estate marketplace Opendoor (NASDAQ:OPEN) is poised to be the latest de-SPAC to take a double-digit jump on earnings as it heads towards the weekend up +10%, having spiked as high as +27% earlier in the day. The movement comes as the former Social Capital II target reported progress towards profitability despite a high rates...
At the SPAC of Dawn Coinbase (NASDAQ:COIN) notched a surprise profit of over $1.5 billion in the first quarter of 2024, well exceeding estimates, demonstrating the powerful effect of publicly traded ETFs have had on crypto marketplaces since the start of the year. The result has pushed the company to bump up its own guidance...
Online casino and sports company Rush Street (NYSE:RSI) is up +18.4% in trading today on the back of a solid first quarter earnings release, bringing the company’s stock to its highest price since the second half of 2022 (currently $7.60). This makes it the latest in a line of 2020 and 2021 de-SPACs that have...
Mountain Crest V (NASDAQ:MCAG) broke a long dealmaking silence by SPACs this morning, albeit with a non-binding agreement to combine with Seoul-based diagnostic biotech firm CUBEBIO. The term sheet would give the company a $620 million pre-transaction equity value and help accelerate the rollout of CUBEBIO’s CEED-NOVUS cancer screening kit products. The company signed an...
Churchill Capital Corp IX (NASDAQ:CCIXU) announced the pricing of its $250 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CCIXU”, Thursday, May 2, 2024. The new SPAC will conduct a broad search and has not limited itself to any particular sector or focus, but it plans to...